STAT+: FDA panel to weigh Grail’s Galleri test

An upcoming meeting of a Food and Drug Administration advisory panel will evaluate Grail’s Galleri test, a multi-cancer early detection blood test.

The review of the Galleri test is part of broader developments in the biotech sector, which also include toxicity challenges facing radiopharma treatments and new regulatory guardrails implemented by China regarding its biotechnology innovation sector.